Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Department of Endocrinology, Institute of Postgraduate Medical education and Research (IPGMER), Kolkata, India.
Ann Palliat Med. 2024 Jan;13(1):162-177. doi: 10.21037/apm-23-113. Epub 2023 Dec 11.
Hypovitaminosis D has been proposed as a risk factor for increased susceptibility to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and severe outcomes in coronavirus disease 2019 (COVID-19). Likewise, vitamin D supplementation has been proposed as an effective means for preventing and improving clinical outcomes in COVID-19. Nevertheless, available data are markedly inconsistent and contradictory. Considering the heterogeneity in the available clinical evidence, we planned to undertake a narrative review and provide a precise summary of the role of vitamin D in COVID-19.
PubMed/MEDLINE database was searched from inception till September 30, 2023 using appropriate MeSH terms. The initial search revealed 900 results. Thereafter, titles and abstracts were scanned and commentaries, letters, and editorials were excluded. Relevant observational studies and clinical trials/randomized controlled trials (RCTs) were full-text assessed and pertinent data were extracted for this narrative review.
Data from observational and ecological studies suggest that hypovitaminosis D is associated with a higher risk of acquiring COVID-19. Similarly, evidence support a negative association between 25-hydroxyvitamin D levels and COVID-19 severity, nevertheless, causality remains to be established. With regard to vitamin D supplementation and COVID-19-related health outcomes, data from observational studies and RCTs are contradictory. Even in moderate-to-severe/severe COVID-19, vitamin D supplementation has not been shown to be beneficial. Besides, data suggest that vitamin D levels might alter COVID-19 vaccine efficacy and be associated with long COVID.
Vitamin D deficiency is linked to an increased risk of acquiring SARS-CoV-2 infection and poor COVID-19 prognosis, however, available evidence with regard to improved clinical outcomes with vitamin D supplementation is inconsistent.
维生素 D 缺乏被认为是增加严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染易感性和 2019 年冠状病毒病(COVID-19)严重结局的危险因素。同样,维生素 D 补充被认为是预防和改善 COVID-19 临床结局的有效手段。然而,现有数据明显不一致且相互矛盾。鉴于现有临床证据的异质性,我们计划进行叙述性综述,并对维生素 D 在 COVID-19 中的作用提供精确总结。
使用适当的 MeSH 术语,从 2023 年 9 月 30 日起,在 PubMed/MEDLINE 数据库中进行搜索。最初的搜索结果显示有 900 个结果。然后,扫描标题和摘要,并排除评论、信件和社论。对相关的观察性研究和临床试验/随机对照试验(RCT)进行全文评估,并提取相关数据进行本叙述性综述。
来自观察性和生态学研究的数据表明,维生素 D 缺乏与 COVID-19 感染风险增加相关。同样,有证据支持 25-羟维生素 D 水平与 COVID-19 严重程度之间存在负相关,但因果关系仍有待确定。关于维生素 D 补充与 COVID-19 相关健康结局的问题,观察性研究和 RCT 的数据相互矛盾。即使在中重度/重度 COVID-19 中,维生素 D 补充也没有显示出有益的效果。此外,数据表明维生素 D 水平可能会改变 COVID-19 疫苗的效力,并与长新冠相关。
维生素 D 缺乏与 SARS-CoV-2 感染风险增加和 COVID-19 预后不良相关,但关于维生素 D 补充改善临床结局的证据不一致。